Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Komrokji on the Potential Implications of the COMMANDS trial in MDS

July 20th 2023

Rami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

Treatment Approaches for Lower-Risk MDS With RAS Mutations

July 20th 2023

The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.

Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

July 20th 2023

Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.

FDA Grants Fast Track Status to Selinexor for Myelofibrosis

July 19th 2023

The FDA has granted a fast track designation to selinexor for use in the treatment of patients with myelofibrosis, including primary myelofibrosis, post–essential thrombocytopenia myelofibrosis, and post–polycythemia vera myelofibrosis.

The Role of Transplant in the Treatment of Patients With MF

July 17th 2023

Dr Abdulraheem Yacoub explains allogeneic hematopoietic cell transplantation in myelofibrosis, the only known curative treatment modality.

Reviewing the Types of Myelofibrosis

July 17th 2023

The panel reviews the types of myelofibrosis, discusses how to risk stratify and explains the role of biomarker testing in patients with MF.

Dr Komrokji on the Implications of the COMMANDS Trial in MDS

July 14th 2023

Rami Komrokji, MD, discusses the clinical implications of the phase 3 COMMANDS trial in patients with very low–, low-, or intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.

Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

July 13th 2023

Panelists review the presented patient profile and shares how they would have approached treatment.

Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

July 13th 2023

Dr Brunner presents the patient profile of a 75-year-old man with transfusion-dependent, lower-risk MDS and symptomatic anemia.

Anemia-Focused Treatment Approaches Represent Future Directions in Myelofibrosis

July 12th 2023

Anna B. Halpern, MD, discusses strides in the treatment of myelofibrosis with anemia, the shifting role of ruxolitinib in this disease, and the importance of providing patients with access to clinical trials.

Ropeginterferon alfa-2b for the Treatment of PV

July 10th 2023

Dr Jamile Shammo reviews recent data on the treatment of patients with polycythemia vera with ropeginterferon.

Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

July 10th 2023

Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.

Ruxolitinib for the Management of PV

July 10th 2023

Abdulraheem Yacoub, MD, reviews data from the RESPONSE and RESPONSE-2 trials on the use of ruxolitinib for the treatment of polycythemia vera.

Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

July 10th 2023

Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.

Navtemadlin With Ruxolitinib Leads to SVR Benefit in TP53 Wild-Type Myelofibrosis

July 7th 2023

John O. Mascarenhas, MD, discusses the design and rationale of the KRT-232-109 trial, key findings from the trial, and potential future directions of the study.

FDA Lifts Partial Clinical Hold on TakeAim Leukemia Trial of Emavusertib in AML/MDS

July 6th 2023

The FDA has lifted a partial clinical hold on the phase 1/2 TakeAim Leukemia trial evaluating emavusertib monotherapy and in combination with azacitidine and venetoclax in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.

Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

July 3rd 2023

The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

Selecting a Frontline Therapy for Patients With PV

July 3rd 2023

Jamile Shammo, MD, explains how she decides on the most appropriate treatment option for a patient with polycythemia vera.

First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

July 3rd 2023

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Current Treatment Landscape for Patients With PV

July 3rd 2023

Drs Rampal and Yacoub details the currently available treatment options and reviews the rationale for use in patients with PV.